Compare OSW & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OSW | TRVI |
|---|---|---|
| Founded | 2017 | 2011 |
| Country | Bahamas | United States |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.5B |
| IPO Year | 2019 | 2019 |
| Metric | OSW | TRVI |
|---|---|---|
| Price | $28.20 | $18.15 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 11 |
| Target Price | ★ $27.00 | $21.55 |
| AVG Volume (30 Days) | 802.3K | ★ 1.6M |
| Earning Date | 04-29-2026 | 05-05-2026 |
| Dividend Yield | ★ 0.81% | N/A |
| EPS Growth | N/A | ★ 31.91 |
| EPS | ★ 0.21 | N/A |
| Revenue | ★ $961,001,000.00 | N/A |
| Revenue This Year | $7.49 | N/A |
| Revenue Next Year | $8.52 | N/A |
| P/E Ratio | $129.81 | ★ N/A |
| Revenue Growth | ★ 7.37 | N/A |
| 52 Week Low | $19.06 | $5.41 |
| 52 Week High | $29.25 | $18.16 |
| Indicator | OSW | TRVI |
|---|---|---|
| Relative Strength Index (RSI) | 69.73 | 72.77 |
| Support Level | $19.70 | $10.07 |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 1.16 | 0.87 |
| MACD | 0.27 | 0.38 |
| Stochastic Oscillator | 82.98 | 94.10 |
OneSpaWorld Holdings Ltd is an operator of health and wellness centers onboard cruise ships and an operator of health and wellness centers at destination resorts all over the world. It offers a suite of premium health, fitness, beauty, and wellness services and products. The services provided by the company include body, salon, and skin care services and products, fitness classes and personal fitness training and pain management, detoxifying programs, and comprehensive body composition analyses among others. The company has only one single segment of Maritime and Destination Resorts.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, non-IPF interstitial lung disease, or non-IPF ILD, and refractory chronic cough, or RCC. Haduvio is an oral extended-release formulation of nalbuphine. The Company operates and manages its business as one reportable segment. Such a segment is the business of developing and commercializing the investigational therapy Haduvio.